2025 Europe Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report
Description
The 2025 Europe Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in Europe are Lonza (Switzerland), Thermo Fisher Scientific (US-origin with European operations), Catalent Inc. (US-origin with European operations), and WuXi Advanced Therapies (China-origin with growing presence in Europe). Lonza leads with about 14-17% market share, offering end-to-end manufacturing from preclinical development to commercial supply, and recently expanding viral vector and allogeneic cell therapy production. Thermo Fisher Scientific integrates manufacturing equipment with advanced cell therapy solutions, including modular systems for lentiviral production. Catalent has rapidly expanded viral vector and cell therapy services, emphasizing rare disease treatments, while WuXi advanced digital twin technology for optimized production, growing their European footprint.
Lonza's central role in European biotech is supported by its extensive network of facilities and strategic acquisitions, ensuring compliance with EMA and other regulatory frameworks. Thermo Fisher's new 44,000 sq. ft. cGMP center near UCSF supports both development and commercial manufacturing. Catalent's upgraded GMP-grade plasmid DNA production in Maryland supports global pipelines, including Europe. WuXi enhanced lentiviral and AAV vector capacity to meet demand for gene-modified therapies. These companies collectively drive innovation and scalability in Europe's cell and gene therapy manufacturing, supported by strong regulatory alignment and significant investment in advanced bioprocessing technologies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in Europe are Lonza (Switzerland), Thermo Fisher Scientific (US-origin with European operations), Catalent Inc. (US-origin with European operations), and WuXi Advanced Therapies (China-origin with growing presence in Europe). Lonza leads with about 14-17% market share, offering end-to-end manufacturing from preclinical development to commercial supply, and recently expanding viral vector and allogeneic cell therapy production. Thermo Fisher Scientific integrates manufacturing equipment with advanced cell therapy solutions, including modular systems for lentiviral production. Catalent has rapidly expanded viral vector and cell therapy services, emphasizing rare disease treatments, while WuXi advanced digital twin technology for optimized production, growing their European footprint.
Lonza's central role in European biotech is supported by its extensive network of facilities and strategic acquisitions, ensuring compliance with EMA and other regulatory frameworks. Thermo Fisher's new 44,000 sq. ft. cGMP center near UCSF supports both development and commercial manufacturing. Catalent's upgraded GMP-grade plasmid DNA production in Maryland supports global pipelines, including Europe. WuXi enhanced lentiviral and AAV vector capacity to meet demand for gene-modified therapies. These companies collectively drive innovation and scalability in Europe's cell and gene therapy manufacturing, supported by strong regulatory alignment and significant investment in advanced bioprocessing technologies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
